参考文献/References:
[1]唐娟,杨阳,王鹤晓,等.人乳头瘤病毒免疫学机制的研究进展[J].国际皮肤性病学杂志,2015,41(5):342-344. [2]谢幸,苟文丽.妇产科学[M].北京:人民卫生出版社,2013:409. [3]Fan X,Liu Y,Heilman SA,et al.Human papilloma virus E7 induces rereplication in response to damage[J].J Virol,2013,87(2):1200-1210. [4]IARC Wording Group on the Evaluation of Carcinogenic Risks to Humans,Biological Agents,Volume 100 B.A review of human carcinogens[D].Iarc Monographs on the Evaluation of Carcinogenic Risks to Humans,2012. [5]Dodd RH,McCafferv KJ,Marlow LA,et al.Knowledge of human papillomavirus（HPV）testing in theUSA,the UK and Australia:an international survey[J].Infections Sexually Transmitted, 2014,90(3):201-207. [6]Graham SV.Human papilloma virus E2 protein:linking replication,transcription,and RNA processing[J].J Virol,2016,90(19):8334-8388. [7]Wardak S.Human papilloma virus (HPV)and cervical cancer[J].Med Dosw Mikrobiol,2016,68(1):73-84. [8]Zivadinovic R,Petric A,Lilic G,et al.Persistent human papilloma virus infection in the etiology of cervical carcinoma:the role of immunological,genetic,viral and cellular factors [J].Srp Arh Celok Lek,2014,142(5-6):378-383. [9]Mellman Ira,Coukos George,Dranoff Glenn.Cancer immunotherapy comes of age[J].Nature, 2011,480(7378):480-489. [10]Conesa-Zamora P.Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV induced immune escape [J].Gynecol Oncol,2013,13(2):480-488. [11]Amador-Molina A,Hernández-Valencia JF,Lamoyi E,et al.Role of Innate Immunity against Human Papillomavirus(HPV)Infections and Effect of Adjuvants in Promoting Specific Immune Response[J].Viruses,2013,5(11):2624-2642. [12]Hibma MH.The immune response to papilloma virus during infection persistence and regression[J].Open Virol J,2012,6(1):241-248. [13]朱宁,程浩.人乳头瘤病毒感染对朗格汉斯细胞影响机制的研究进展[J].国际皮肤性病学杂志,2011,37(3):174-176. [14]Lucs AV,Devoti JA,Hatam L,et al.Immune Dysregulation in Patients Persistently Infected with Human Papillomaviruses 6 and 11[J].Journal of Clinical Medicine,2015,4(3):375-388. [15]Song D,Li H,Li H,et al.Effect of human papilloma virus infection on the immune system and its role in the course of cervical cancer[J].Oncol Lett,2015,10(2):600-606. [16]蒋桔莲,陈健,钟倩怡,等.宫颈癌及癌前病变患者HPV感染与机体免疫状态的研究[J].浙江医学,2015,37(19):1578-1581. [17]Li B,Zheng X,Hu C,et al.Human papillomavirus genome-wide identification of T-cell epitopes for peptide vaccine development against cervical cancer:an integration of computational analysis and experimental assay[J].J Comput Biol,2015,22(10):962-974. [18]辛丹丹,佐满珍,刘朝奇.调节性T细胞与人乳头瘤病毒感染宫颈癌的相关性研究进展[J].海南医学,2015,26(10):1480-1483. [19]Andersen AS,Koldjaer Solling AS,Ovesen T,et al.The interplay between HPV and host immunity in head and neck squamous cell carcinoma[J].Int J Cancer,2014,134(12):2755-2763. [20]Yu Y,Zou JJ, DO Laboratory.Relationship and clinical significance between T helper cell and cervical lesions among patient with high risk of HPV infection[J].Chinese Journal of Women and Children Health,2016,7(2):51-54. [21]Miura S,Kawana K,DJ Schust,et al.CD1d,a sentinel molecule bridging innate and adaptive immunity,is downregulated by the human papillomavirus(HPV)E5 protein:a possible mechanism for immune evasion by HPV[J].Journal of Virology,2010,84(22):11614 -11623. [22]Prata TT,Bonin CM,Ferreira AM,et al.Local immunosuppression induced by high viral load of human papillomavirus:characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions[J].Immunology,2015,146(1):113-121. [23]Rosales R,Rosales C.Immune therapy for human papilloma virus-related cancers[J].World Journal of Clinical Oncology,2014,5(5):1002-1019. [24]孟晶炜,宋静慧.宫颈病变患者阴道局部免疫功能的变化与HPV转归的研究进展[J].国际生殖健康/计划生育杂志,2015,34(6):484-487. [25]Nakahara T,Kiyono T.Regulation of human papilloma virus(HPV)genome replication in the viral life cycle and its association with the viral persistence and cancer development[J].Uirusu,2014,64(1):57-66. [26]Lagunas-Martínez A,Madrid-Marina V,Gariglio P.Modulation of apoptosis by early human papillomavirus proteins in cervical cancer[J].Biochim Biophys Acta,2010,1805(1):6-16. [27]程晓东,谢幸.HPV预防性疫苗应用现状[J].实用妇产科杂志,2017,33(2):86-89. [28]吴宝杰,杨志建.HPV 及其相关疫苗的研究进展[J].医学综述,2018,24(4):662-666. [29]吴娇,齐蔓莉,刘全忠.HPV 疫苗的应用评价[J].中国医学文摘（皮肤科学）,2017,34(1):102-107,109. [30]Herreo R,Gonzalez P,Markowitz LE.Present status of human papilloma virus vaccine development and implementation[J].Lancet Oncol,2015,16(5):e206-e216. [31]王卡娜,郄明蓉.HPV治疗性疫苗研究现状[J].实用妇产科杂志,2017,33(2):89-91.
相似文献/References:
[1]刘洪波,祁晓莉,乔 星,等.HPV分型检测联合TCT检查在宫颈病变筛查中的应用[J].医学信息,2018,31(08):152.[doi:10.3969/j.issn.1006-1959.2018.08.053]
LIU Hong-bo,QI Xiao-li,QIAO Xing,et al.Application of HPV Typing Test Combined with TCT Examination in Screening Cervical Lesions[J].Medical Information,2018,31(19):152.[doi:10.3969/j.issn.1006-1959.2018.08.053]
[2]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者
分流中的作用分析[J].医学信息,2018,31(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Medical Information,2018,31(19):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[3]莫宗平,刘 巧,蒋佳利.安岳地区女性高危型HPV基因分型结果分析[J].医学信息,2018,31(18):101.[doi:10.3969/j.issn.1006-1959.2018.18.031]
MO Zong-ping,LIU Qiao,JIANG Jia-li.Analysis of the Results of High-risk HPV Genotyping in Women in Anyue Area[J].Medical Information,2018,31(19):101.[doi:10.3969/j.issn.1006-1959.2018.18.031]
[4]朱 军,张振君.妇女宫颈病变筛查分析[J].医学信息,2019,32(01):139.[doi:10.3969/j.issn.1006-1959.2019.01.043]
ZHU Jun,ZHANG Zhen-jun.Screening Analysis of Cervical Lesions in Women[J].Medical Information,2019,32(19):139.[doi:10.3969/j.issn.1006-1959.2019.01.043]
[5]许生样.杭州地区男性人乳头瘤病毒感染特征分析[J].医学信息,2020,33(05):137.[doi:10.3969/j.issn.1006-1959.2020.05.043]
XU Sheng-yang.Characteristics of Human Papillomavirus Infection in Male in Hangzhou[J].Medical Information,2020,33(19):137.[doi:10.3969/j.issn.1006-1959.2020.05.043]
[6]秦燕,王杏茶,方淑琴,等.承德市女性人乳头瘤病毒感染基因分型的临床分析[J].医学信息,2020,33(08):144.[doi:10.3969/j.issn.1006-1959.2020.08.047]
QIN Yan,WANG Xing-cha,FANG Shu-qin,et al.Infection Status and Distribution Characteristics of Female HPV Subtypes in Chengde City from 2014 to 2017[J].Medical Information,2020,33(19):144.[doi:10.3969/j.issn.1006-1959.2020.08.047]
[7]代艳文,吴大富.宜昌地区妇女人乳头瘤病毒感染状况分析[J].医学信息,2020,33(16):143.[doi:10.3969/j.issn.1006-1959.2020.16.045]
DAI Yan-wen,WU Da-fu.Analysis of Women’s Human Papillomavirus Infection in Yichang Area[J].Medical Information,2020,33(19):143.[doi:10.3969/j.issn.1006-1959.2020.16.045]
[8]刘琳琳,宫 正,杨海嵘,等.宫颈癌的诊治及预防研究[J].医学信息,2021,34(03):49.[doi:10.3969/j.issn.1006-1959.2021.03.015]
LIU Lin-lin,GONG Zheng,YANG Hai-rong,et al.Research on Diagnosis,Treatment and Prevention of Cervical Cancer[J].Medical Information,2021,34(19):49.[doi:10.3969/j.issn.1006-1959.2021.03.015]
[9]张 晴,杨勇莉.p16在宫颈癌发生发展中的作用[J].医学信息,2022,35(01):59.[doi:10.3969/j.issn.1006-1959.2022.01.014]
ZHANG Qing,YANG Yong-li.Role of p16 in the Development of Cervical Cancer[J].Medical Information,2022,35(19):59.[doi:10.3969/j.issn.1006-1959.2022.01.014]
[10]周爱萍.重组人干扰素α-2b注射液联合凝胶对宫颈HPV感染患者炎性因子水平的影响[J].医学信息,2022,35(06):162.[doi:10.3969/j.issn.1006-1959.2022.06.042]
ZHOU Ai-ping.Effect of Recombinant Human Interferon α-2b Injection Combined with Gel on Inflammatory Factor Levels in Patients with Cervical HPV Infection[J].Medical Information,2022,35(19):162.[doi:10.3969/j.issn.1006-1959.2022.06.042]